C5 and paroxysmal nocturnal hemoglobinuria: Those five patients were all adults and were treated with anti-complement C5 monoclonal antibodies (Eculizumab or ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH) (see below in Section 3.2) [14,15].